CENTOGENE N.V. (CNTG): Price and Financial Metrics


CENTOGENE N.V. (CNTG): $2.69

-0.01 (-0.37%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

CNTG Stock Summary

  • The capital turnover (annual revenue relative to shareholder's equity) for CNTG is 5.84 -- better than 93.81% of US stocks.
  • Centogene NV's stock had its IPO on November 7, 2019, making it an older stock than merely 6.38% of US equities in our set.
  • As for revenue growth, note that CNTG's revenue has grown 179.58% over the past 12 months; that beats the revenue growth of 95.42% of US companies in our set.
  • Stocks that are quantitatively similar to CNTG, based on their financial statements, market capitalization, and price volatility, are IMMR, QTRX, AUPH, NVVE, and CASI.
  • CNTG's SEC filings can be seen here. And to visit Centogene NV's official web site, go to www.centogene.com.

CNTG Price Target

For more insight on analysts targets of CNTG, see our CNTG price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.

Average Price Target $19.32 Average Broker Recommendation 1 (Strong Buy)

CNTG Stock Price Chart Interactive Chart >

Price chart for CNTG

CNTG Price/Volume Stats

Current price $2.69 52-week high $11.95
Prev. close $2.70 52-week low $2.69
Day low $2.69 Volume 5,300
Day high $2.73 Avg. volume 12,331
50-day MA $3.69 Dividend yield N/A
200-day MA $6.52 Market Cap 53.42M

CENTOGENE N.V. (CNTG) Company Bio


Centogene NV is a commercial-stage company. It focuses on rare diseases that transform real-world clinical and genetic data into actionable information for patients, physicians and pharmaceutical companies. It operates through the following two segments: Pharmaceutical and Diagnostics. The Pharmaceutical segment provides services to pharmaceutical partners, including early patient recruitment and identification, epidemiological insights, biomarker discovery and patient monitoring. The Diagnostics segment provides targeted genetic sequencing and diagnostics services. The company was founded by Arndt Rolf and Christoph Ehlers in 2006 and is headquartered in Rostock, Denmark.


CNTG Latest News Stream


Event/Time News Detail
Loading, please wait...

CNTG Latest Social Stream


Loading social stream, please wait...

View Full CNTG Social Stream

Latest CNTG News From Around the Web

Below are the latest news stories about Centogene NV that investors may wish to consider to help them evaluate CNTG as an investment opportunity.

CENTOGENE Announces Voting Results of Extraordinary General Meeting

CAMBRIDGE, Mass. and ROSTOCK, Germany and BERLIN, Feb. 22, 2022 (GLOBE NEWSWIRE) -- Centogene N.V. (Nasdaq: CNTG), a commercial-stage company focused on generating data-driven insights to diagnose, understand, and treat rare diseases, today announced the voting results of the Company’s Extraordinary General Meeting. The shareholders of the Company voted in favor of all proposals, which included the appointments of Kim Stratton as Managing Director and Prof. Andreas Busch as Supervisory Director.

Yahoo | February 22, 2022

Centogene announces CFO transition, picks interim CFO

Centogene (CNTG) plans for the transition of CFO René Just and the appointment of Miguel Coego Rios as EVP, Finance & Legal and Interim CFO.René Just has resigned effective Mar.31,…

Seeking Alpha | February 8, 2022

CENTOGENE Announces CFO Transition and Appointment of Miguel Coego Rios as EVP Finance & Legal and Interim CFO

CAMBRIDGE, Mass. and ROSTOCK, Germany, and BERLIN, Feb. 08, 2022 (GLOBE NEWSWIRE) -- Centogene N.V. (Nasdaq: CNTG), a commercial-stage company focused on generating data-driven insights to diagnose, understand, and treat rare diseases, today announced plans for the transition of Chief Financial Officer René Just and the appointment of Miguel Coego Rios as Executive Vice President of Finance & Legal and Interim CFO. René Just has resigned from the Company effective March 31, 2022, after the expec

Yahoo | February 8, 2022

Centogene Raises $62M Via Debt And Equity Financings To Support Growth Plan

Centogene N.V. (NASDAQ: CNTG) has closed a €15 million (approximately $17 million) private placement financing from investors led by DPE Deutsche Private Equity, TVM Capital Life Science, and Careventures. The private placement financing includes the sale of 4.5 million shares at $3.73 and warrants to acquire up to 1.34 million additional shares at an exercise price per share of $7.72. The Company has announced a $45 million senior secured loan facility provided by Oxford Finance LLC, a specialt

Yahoo | February 1, 2022

CENTOGENE Announces Nomination of Andreas Busch to Supervisory Board

Nomination adds significant expertise to support pharma partnerships and an impressive track record in value creationCAMBRIDGE, Mass. and ROSTOCK, Germany, and BERLIN, Feb. 01, 2022 (GLOBE NEWSWIRE) -- Centogene N.V. (Nasdaq: CNTG), a commercial-stage company focused on generating data-driven insights to diagnose, understand, and treat rare diseases, today announced the nomination of Prof. Andreas Busch as a member of the Supervisory Board, which will be proposed to the shareholders at the next

Yahoo | February 1, 2022

Read More 'CNTG' Stories Here

CNTG Price Returns

1-mo -28.27%
3-mo -29.42%
6-mo -61.07%
1-year -73.86%
3-year N/A
5-year N/A
YTD -48.55%
2021 -51.50%
2020 7.05%
2019 N/A
2018 N/A
2017 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.5103 seconds.